Stifel initiated coverage of Palisade Bio (PALI) with a Buy rating and $5 price target The firm, which views inflammatory bowel disease as a large, validated commercial market where clinical efficacy has largely been stagnant since the approval of Entyvio more than a decade ago, sees Palisade as “well-positioned within this landscape” with PALI-2108, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio announces presentation of new data for PALI-2108
- Palisade Bio appoints Verstockt to its Clinical Advisory Board
- Palisade Bio appoints Peyrin-Biroulet, Rubin to Clinical Advisory Board
- Palisade Bio initiated with a Buy at B. Riley
- Palisade Bio announces equity investment from Crohn’s & Colitis Foundation